Articles by Sanjay Garg, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Sanjay Garg, PhD

Sanjay Garg, PhD

Associate Professor

Sanjay Garg, PhD, is an associate professor at the School of Pharmacy, University of Auckland, Auckland, New Zealand, and a member of the Pharmaceutical Technology Editorial Advisory Board.

Articles
Biopharmaceutical Form and Function
June 2, 2010

A timely new book explains techniques for conformational analysis.

Quality in, Quality Out
June 2, 2009

A book guides readers through the regulatory requirements for computerized quality systems.

A Peak in Mass-Spectrometry Literature
December 2, 2008

A book about pharmaceutical analysis engages the reader with history and unexpected asides.

Charting a Path to Purity
October 2, 2007

Regulators and industry professionals provide a guide for identifying and measuring impurities.

An Update on Osmotic Drug Delivery
August 2, 2003

The authors review patent literature that describes new developments in osmotic drug delivery such as pulsatile, delayed, and volume amplifier delivery devices.

Current Status of Drug Delivery Technologies and Future Directions
February 2, 2001

Evolution of an existing drug molecule from a conventional form to a novel delivery system can significantly improve its performance in terms of patient compliance, safety, and efficacy. These days,drug delivery companies are engaged in the development of multiple platform technologies to get competitive advantage, extend patent life, and increase market share of their products.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
FindPharma Custom Search
Click here